In many previously published articles, rheumatologists have recommended that serum AQP4 and myelin oligodendrocyte glycoprotein antibodies should be considered for all patients with CTD with myelitis, bilateral optic neuritis, and large fusion brain damage (30–34). Here, AQP4 is linked to myelitis.